Additional Relevant Details Despite its announced partnership with Receptor Life Sciences last week, MannKind (MNKD) still faces short- and mid-term liquidity problems. MNKD will soon find itself with no way to commercialize Afrezza, its headline insulin drug, since Sanofi (SNY) “cut its ties with Afrezza and will no longer support its marketing costs in the United States.”  After the split with SNY, MNKD expects $59-60 million in cash; they are $185.4 million in debt.  Any company interested in MannKind’s assets would likely get a better deal by waiting until they are forced to declare bankruptcy.